Javlor for metastatic carcinoma of the urothelial tract

Pierre Fabre has launched Javlor (vinflunine) as monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen.

Vinflunine is a vinca alkaloid agent, it acts mainly as a mitotic spindle poison to impair chromosomal segregation during mitosis.

Secondary analyses of a randomised clinical trial in patients with advanced or metastatic transitional cell carcinoma of the urothelium, as second line therapy after failure of a prior platinum containing regimen, confirmed the clinical efficacy of vinflunine compared to best standard of care alone.

The efficacy and safety of vinflunine have not been studied in patients with Performance Status ≥2.

As with all vinca alkaloids and analogues, vinflunine is fatal if given intrathecally. Only personnel trained in the use of vinca alkaloids and analogues should be involved in the management of patients with vinflunine.

View Javlor drug record

Further information: Pierre Fabre

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Elleste Duet, Elleste Solo, Diprosone and Livial.

Potentially addictive medicines 'being prescribed for years'

Potentially addictive medicines 'being prescribed for years'

Hundreds of thousands of people are receiving prescriptions...

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.